Understanding how cells differentiate during early embryonic development is crucial for advancing regenerative medicine and ...

ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, but remains in very early clinical stages. See why I ...

A team of researchers led by Prof. Xiao Jun from the Institute of Genetics and Developmental Biology (IGDB) of the Chinese ...

About ORIC-944 ORIC-944 is a potent and selective allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit that demonstrates best-in ...

ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer ...

Specifically, PRC2 adds a well-known repressive tag called ... TOE1 directly interacts with the INO80-C chromatin remodeling complex to remove H2A.Z from nucleosomes at embryonic gene loci ...

The importance of PRC2 in human tumors is well established ... For example, the H3K4me3 histone methyltransferase MLL2 assembles a protein complex containing UTX, which demethylates H3K27me3 ...

Abstract HighlightsORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility ...